Mediwound Ltd. (MDWD) 6.74 $MDWD
MediWound to Present at Oppenheimer 25th Annual Healthcare Conference
Business Wire - Tue Dec 09, 8:01AM CST
MediWound Ltd. (Nasdaq:MDWD), a fully integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that Company management will participate at the Oppenheimer 25th Annual Healthcare Conference taking place from December 10-11, 2014 in New York City. Gal Cohen, President and Chief Executive Officer of MediWound, will be presenting a corporate overview on Thursday, December 11th at 3:20 p.m. Eastern time.
MDWD: 6.74 (+0.19)
5 Stocks Ready for Breakouts: MediWound and More
at The Street - Thu Dec 04, 8:44AM CST
These are the stocks that often go on to make monster moves to the upside.
NAME: 7.98 (-0.14), KRA: 18.74 (-0.17), MDWD: 6.74 (+0.19), TRNX: 26.39 (-0.14), JD: 23.97 (-0.82)
MediWound to Present at Two Upcoming Investor Conferences
Business Wire - Thu Nov 06, 7:01AM CST
MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that MediWound's management team will be presenting the Company's corporate overview at the following investor conferences in November.
MDWD: 6.74 (+0.19)
MediWound EPS in-line
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 4:32PM CST
MDWD: 6.74 (+0.19)
MediWound Reports Third Quarter 2014 Financial Results
Business Wire - Wed Nov 05, 3:00PM CST
MediWound Ltd. (Nasdaq:MDWD), a fully integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today reported financial results for the three and nine months ended September 30, 2014.
MDWD: 6.74 (+0.19)
MediWound Initiates Post-Marketing Study with NexoBrid(R) to Treat Severe Burns in Pediatric Patients
Business Wire - Mon Nov 03, 6:30AM CST
MediWound Ltd. (Nasdaq: MDWD), a fully-integrated, biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the Company has commenced a European post-marketing (Phase 3) Pediatric Investigation Plan (PIP) study to evaluate the efficacy and safety of NexoBrid(R) as a treatment for severe burns in children. MediWound is conducting this study as part of the European legislation concerning the development and authorization of medicines for use in children in Europe.
MDWD: 6.74 (+0.19)
MediWound reports November 5
Seeking Alpha - at Seeking Alpha - Sat Nov 01, 5:06PM CDT
MDWD: 6.74 (+0.19)
MediWound to Host Third Quarter 2014 Financial Results Conference Call on November 5, 2014 at 4:30 p.m. Eastern Time
Business Wire - Wed Oct 29, 6:00AM CDT
MediWound Ltd. (Nasdaq:MDWD), a fully-integrated, biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the Company will release financial results for the three and nine months ended September 30, 2014, after the market close on Wednesday, November 5, 2014.
MDWD: 6.74 (+0.19)
MediWound's NexoBrid to be Featured at International Society for Burn Injuries 2014
GlobeNewswire - Tue Oct 07, 8:12AM CDT
MediWound Ltd. (Nasdaq:MDWD), a fully-integrated, biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the Company's NexoBrid(R) will be featured in multiple oral and poster presentations at the 17 Congress of the International Society for Burn Injuries (ISBI) taking place October 12-16, 2014 in Sydney, Australia. The presentation abstracts will be available online at www.isbi.org.
MDWD: 6.74 (+0.19)
4 Under-$10 Stocks to Trade for Breakouts
at The Street - Fri Sep 12, 8:03AM CDT
These stocks under $10 are within range of triggering breakout trades.
MDWD: 6.74 (+0.19), SIGA: 1.51 (-0.01), SNMX: 5.35 (+0.01), XOMA: 4.68 (-0.02)
MediWound Reports Second Quarter 2014 Financial Results
GlobeNewswire - Thu Jul 31, 5:00AM CDT
MediWound Ltd. (Nasdaq:MDWD), a fully integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today reported financial results for the three and six months ended June 30, 2014.
MDWD: 6.74 (+0.19)
MediWound to Host Second Quarter 2014 Financial Results Conference Call on July 31, 2014 at 8:30 a.m.
GlobeNewswire - Tue Jul 22, 5:30AM CDT
MediWound Ltd. (Nasdaq:MDWD), a fully-integrated, biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the Company will release financial results for the three and six months ended June 30, 2014, before the market open on Thursday, July 31, 2014.
MDWD: 6.74 (+0.19)
MediWound Announces NexoBrid Marketing Approval From Israeli Ministry of Health
GlobeNewswire - Wed Jul 16, 5:30AM CDT
MediWound Ltd. (Nasdaq:MDWD), a fully-integrated, biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, announced today that the Company has received authorization from the Israeli Ministry of Health to market and distribute NexoBridfor the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns. MediWound intends to launch NexoBrid in Israel this quarter.
MDWD: 6.74 (+0.19)
MediWound (MDWD) Falls: Stock Goes Down 6.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jul 14, 7:47AM CDT
Shares of MediWound fell over 6% on Friday and witnessed flat revisions in current year estimates in the past few weeks suggest a close watch of the firm in near future.
ENDP: 68.77 (-2.45), ESPR: 37.48 (-1.00), BCRX: 10.06 (+0.02), MDWD: 6.74 (+0.19)
MediWound to Present at Oppenheimer 25th Annual Healthcare Conference
Business Wire - Tue Dec 09, 8:01AM CST
MediWound Ltd. (Nasdaq:MDWD), a fully integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that Company management will participate at the Oppenheimer 25th Annual Healthcare Conference taking place from December 10-11, 2014 in New York City. Gal Cohen, President and Chief Executive Officer of MediWound, will be presenting a corporate overview on Thursday, December 11th at 3:20 p.m. Eastern time.
MDWD: 6.74 (+0.19)
5 Stocks Ready for Breakouts: MediWound and More
at The Street - Thu Dec 04, 8:44AM CST
These are the stocks that often go on to make monster moves to the upside.
NAME: 7.98 (-0.14), KRA: 18.74 (-0.17), MDWD: 6.74 (+0.19), TRNX: 26.39 (-0.14), JD: 23.97 (-0.82)
MediWound to Present at Two Upcoming Investor Conferences
Business Wire - Thu Nov 06, 7:01AM CST
MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that MediWound's management team will be presenting the Company's corporate overview at the following investor conferences in November.
MDWD: 6.74 (+0.19)
MediWound EPS in-line
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 4:32PM CST
MDWD: 6.74 (+0.19)
MediWound Reports Third Quarter 2014 Financial Results
Business Wire - Wed Nov 05, 3:00PM CST
MediWound Ltd. (Nasdaq:MDWD), a fully integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today reported financial results for the three and nine months ended September 30, 2014.
MDWD: 6.74 (+0.19)
MediWound Initiates Post-Marketing Study with NexoBrid(R) to Treat Severe Burns in Pediatric Patients
Business Wire - Mon Nov 03, 6:30AM CST
MediWound Ltd. (Nasdaq: MDWD), a fully-integrated, biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the Company has commenced a European post-marketing (Phase 3) Pediatric Investigation Plan (PIP) study to evaluate the efficacy and safety of NexoBrid(R) as a treatment for severe burns in children. MediWound is conducting this study as part of the European legislation concerning the development and authorization of medicines for use in children in Europe.
MDWD: 6.74 (+0.19)
MediWound reports November 5
Seeking Alpha - at Seeking Alpha - Sat Nov 01, 5:06PM CDT
MDWD: 6.74 (+0.19)
MediWound to Host Third Quarter 2014 Financial Results Conference Call on November 5, 2014 at 4:30 p.m. Eastern Time
Business Wire - Wed Oct 29, 6:00AM CDT
MediWound Ltd. (Nasdaq:MDWD), a fully-integrated, biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the Company will release financial results for the three and nine months ended September 30, 2014, after the market close on Wednesday, November 5, 2014.
MDWD: 6.74 (+0.19)
MediWound's NexoBrid to be Featured at International Society for Burn Injuries 2014
GlobeNewswire - Tue Oct 07, 8:12AM CDT
MediWound Ltd. (Nasdaq:MDWD), a fully-integrated, biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the Company's NexoBrid(R) will be featured in multiple oral and poster presentations at the 17 Congress of the International Society for Burn Injuries (ISBI) taking place October 12-16, 2014 in Sydney, Australia. The presentation abstracts will be available online at www.isbi.org.
MDWD: 6.74 (+0.19)
4 Under-$10 Stocks to Trade for Breakouts
at The Street - Fri Sep 12, 8:03AM CDT
These stocks under $10 are within range of triggering breakout trades.
MDWD: 6.74 (+0.19), SIGA: 1.51 (-0.01), SNMX: 5.35 (+0.01), XOMA: 4.68 (-0.02)
MediWound Reports Second Quarter 2014 Financial Results
GlobeNewswire - Thu Jul 31, 5:00AM CDT
MediWound Ltd. (Nasdaq:MDWD), a fully integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today reported financial results for the three and six months ended June 30, 2014.
MDWD: 6.74 (+0.19)
MediWound to Host Second Quarter 2014 Financial Results Conference Call on July 31, 2014 at 8:30 a.m.
GlobeNewswire - Tue Jul 22, 5:30AM CDT
MediWound Ltd. (Nasdaq:MDWD), a fully-integrated, biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the Company will release financial results for the three and six months ended June 30, 2014, before the market open on Thursday, July 31, 2014.
MDWD: 6.74 (+0.19)
MediWound Announces NexoBrid Marketing Approval From Israeli Ministry of Health
GlobeNewswire - Wed Jul 16, 5:30AM CDT
MediWound Ltd. (Nasdaq:MDWD), a fully-integrated, biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, announced today that the Company has received authorization from the Israeli Ministry of Health to market and distribute NexoBridfor the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns. MediWound intends to launch NexoBrid in Israel this quarter.
MDWD: 6.74 (+0.19)
MediWound (MDWD) Falls: Stock Goes Down 6.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jul 14, 7:47AM CDT
Shares of MediWound fell over 6% on Friday and witnessed flat revisions in current year estimates in the past few weeks suggest a close watch of the firm in near future.
ENDP: 68.77 (-2.45), ESPR: 37.48 (-1.00), BCRX: 10.06 (+0.02), MDWD: 6.74 (+0.19)
